Edc3 Inhibitors
Edc3 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of Enhancer of mRNA-decapping protein 3 (Edc3), a key regulator in the process of mRNA decay. Edc3 is a multifunctional protein that plays a significant role in the degradation of mRNA, a critical process in post-transcriptional gene regulation. It functions as a scaffold protein that interacts with various components of the decapping complex, including Dcp1 and Dcp2, facilitating the removal of the 5' cap structure from mRNA molecules. This decapping is a pivotal step in mRNA turnover, leading to the subsequent degradation of the mRNA by exonucleases. By regulating mRNA decay, Edc3 influences the stability and availability of mRNA for translation, thereby controlling the expression levels of numerous genes. Inhibiting Edc3 provides researchers with a tool to disrupt the mRNA decay pathway and study the consequences on gene expression and cellular function.
In research settings, Edc3 inhibitors are valuable for exploring the mechanisms by which mRNA stability is controlled and how alterations in mRNA decay impact cellular processes. By blocking Edc3 activity, scientists can investigate the effects on the decapping and degradation of specific mRNAs, leading to changes in the levels of these transcripts and their corresponding proteins. This inhibition allows researchers to study how mRNA decay contributes to gene regulation in various physiological contexts, including responses to environmental changes, cellular stress, and developmental cues. Additionally, Edc3 inhibitors enable the examination of the broader network of protein-protein and protein-RNA interactions involved in mRNA turnover, shedding light on the complex regulatory systems that maintain mRNA homeostasis. Through these studies, the use of Edc3 inhibitors enhances our understanding of post-transcriptional gene regulation, the dynamic nature of mRNA stability, and the intricate control mechanisms that govern gene expression at the level of mRNA decay.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D inhibits Edc3 by interfering with RNA polymerase activity, leading to disruption of mRNA synthesis. This inhibition indirectly affects mRNA decay processes by reducing the pool of newly synthesized transcripts available for processing and degradation. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits Edc3 by specifically targeting RNA polymerase II, thereby impairing mRNA transcription. This inhibition indirectly impacts mRNA decay processes by reducing the synthesis of mRNA transcripts, limiting the substrates available for subsequent degradation pathways. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin inhibits Edc3 by acting as an analog of adenosine, terminating RNA synthesis and reducing the levels of mRNA available for decay. This inhibition indirectly affects mRNA decay processes by limiting the production of mRNA transcripts, thereby reducing the substrates for degradation pathways. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB inhibits Edc3 by targeting the C-terminal domain of RNA polymerase II, leading to inhibition of mRNA transcription. This inhibition indirectly affects mRNA decay processes by reducing the synthesis of mRNA transcripts, thereby limiting the substrates available for degradation pathways. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine inhibits Edc3 by potentially inhibiting several phosphodiesterases, leading to alterations in cellular signaling pathways that indirectly affect mRNA degradation. This inhibition impacts mRNA decay processes by modulating cellular responses and regulatory mechanisms involved in mRNA turnover and degradation. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
Spliceostatin A inhibits Edc3 by binding to the SF3B complex, leading to inhibition of splicing and potential retention of pre-mRNA. This inhibition indirectly influences mRNA decay processes by altering the processing and maturation of mRNA transcripts, thereby affecting their stability and degradation rates. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
Pladienolide B inhibits Edc3 by binding to the spliceosome and disrupting pre-mRNA splicing processes. This inhibition indirectly impacts mRNA decay processes by altering the processing and maturation of mRNA transcripts, potentially leading to their retention or degradation. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $69.00 $266.00 | 8 | |
Mycophenolic acid inhibits Edc3 by inhibiting inosine monophosphate dehydrogenase, potentially affecting mRNA synthesis and decay. This inhibition indirectly influences mRNA decay processes by altering nucleotide metabolism and cellular responses involved in mRNA turnover and stability regulation. | ||||||